Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Summit Therapeutics (SMMT) Non Operating Income: 2022-2025

Historic Non Operating Income for Summit Therapeutics (SMMT) over the last 2 years, with Sep 2025 value amounting to $2.4 million.

  • Summit Therapeutics' Non Operating Income fell 47.18% to $2.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $13.5 million, marking a year-over-year decrease of 46.09%. This contributed to the annual value of $13.4 million for FY2024, which is 19.55% up from last year.
  • According to the latest figures from Q3 2025, Summit Therapeutics' Non Operating Income is $2.4 million, which was down 11.40% from $2.7 million recorded in Q2 2025.
  • Summit Therapeutics' 5-year Non Operating Income high stood at $16.1 million for Q4 2023, and its period low was -$4.4 million during Q3 2022.
  • Its 3-year average for Non Operating Income is $4.2 million, with a median of $2.7 million in 2025.
  • Data for Summit Therapeutics' Non Operating Income shows a peak YoY increase of 689.95% (in 2024) and a maximum YoY decrease of 72.55% (in 2024) over the last 5 years.
  • Quarterly analysis of 4 years shows Summit Therapeutics' Non Operating Income stood at $5.5 million in 2022, then spiked by 194.35% to $16.1 million in 2023, then slumped by 72.55% to $4.4 million in 2024, then crashed by 47.18% to $2.4 million in 2025.
  • Its Non Operating Income was $2.4 million in Q3 2025, compared to $2.7 million in Q2 2025 and $3.9 million in Q1 2025.